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The discovery of unidirectional, ATP-dependent canalicular transport
systems (also termed "export pumps") for bile salts, amphiphilic anion-
ic conjugates, lipophilic cations, and phospholipids has opened new
opportunities for understanding biliary physiology and the pathophysi-
ology ofcholestasis. In addition, ATP-independent canalicular transport
systems for glutathione and bicarbonate contribute to (bile acid-inde-
pendent) bile formation. Canalicular excretion of bile salts and several
non-bile acid organic anions is impaired in various experimental mod-
els of cholestasis. Recent cloning of several canalicular transport sys-
tems now facilitates studies on their molecularregulation in cholestasis.
Although the picture is far from complete, experimental evidence now
exists that decreased or even absent expression of canalicular transport
proteins may explain impaired transport function resulting in hyper-
bilirubinemia and cholestasis. With the increasing availability ofmole-
cular probes for these transport systems in humans, new information on
the molecular regulation of canalicular transport proteins in human
cholestatic liver diseases is beginning to emerge and should bring new
insights into their pathophysiology and treatment. This article gives an
overview on molecular alterations of canalicular transport systems in
experimental models ofcholestasis and discusses the potential implica-
tions of these changes for the pathophysiology ofcholestasis.
PHYSIOLOGY OF CANALICULAR TRANSPORT SYSTEMS
The hepatocyte is a polarized epithelial cell with distinct features of its basolateral
(sinusoidal) and apical (canalicular) plasma membrane domains. The canalicular mem-
brane contains about 10-15 percent of the plasma membrane surface area of the hepato-
cyte and comprises the bile canaliculus. Bile formation begins with formation ofa prima-
ry secretion at the canalicular level ("canalicular bile") by both bile salt-dependent and -
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independent mechanisms, followed by modifications along the bile ductules and ducts [1,
2]. Canalicular bile is formed by osmotic filtration of water and small electrolytes via the
tight junctions in response to osmotic gradients generated by active transport systems
located at the canalicular membrane. The major determinant ofcanalicular bile formation
is the excretion of bile acids into the canaliculus (bile acid-dependent bile flow). In addi-
tion, other (non-bile acid) organic anions and cations and their conjugates also osmotical-
ly influence bile flow. Canalicular excretion ofglutathione and bicarbonate constitute the
major components of the bile acid-independent fraction ofbile flow, although the contri-
bution of bicarbonate occurs mainly at the level of the bile ductules, particularly when
stimulated with hormones and neuropeptides [1, 3].
Initially it was thought that the major driving force for the canalicular excretion ofall
biliary constituents was the intracellular negative membrane potential (-35 mV) generat-
ed by the Na+ pump (Na+/K+-ATPase) at the basolateral membrane. However, it has
become evident that the membrane potential could only account for a 3-fold concentration
gradient and thus is insufficient to explain the large gradients (ranging from 100-fold to as
high as 1000-fold) observed for bile acids and certain anionic conjugates (e.g., cysteinyl
leukotrienes). The discovery of unidirectional, primary active ATP-dependent transport
systems at the canalicular membrane has opened new opportunities for understanding bil-
iary physiology and the pathophysiology of cholestasis. These ATP-dependent transport
systems belong to the ATP-binding cassette transporter superfamily and share common
structural and functional characteristics [4, 5]. At least fourATP-dependent transport sys-
tems (also termed "export pumps") have been identified so far at the canalicular mem-
brane (Figure 1, left panel): (i) A multidrug export pump (MDRI P-glycoprotein) for
hydrophobic cationic compounds (e.g., anticancer drugs, calcium channel blockers,
cyclosporin A, various other drugs) [18, 19], and (ii) a phospholipid pump (MDR3 P-gly-
coprotein) which probably acts as a phospolipid flippase/translocase [20, 21]. The MDR1
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and 3 P-glycoproteins (P-gp) are products of the multidrug-resistance (MDR) genes, and
the MDR3 isoform is predominant in normal liver [19]. (iii) A conjugate export pump
which has recently been cloned in rats [10, 11] and humans [12, 13] and was identified as
the canalicular isoform of the multidrug-resistance-associated protein,(MRP) and there-
fore designated as MRP2. This transport system is functionally also known as the canalic-
ular multispecific organic anion transporter (cMOAT) [14] and mediates the canalicular
excretion of a broad range oforganic anions, most ofwhich are amphiphilic anionic con-
jugates with glutathione, glucuronate and sulfate formed by phase II conjugation in the
hepatocyte [14-17]. (iv) A bile salt export pump (canalicular bile acid transporter, cBAT)
for monovalent bile salts, which functionally is well characterized [6-9] but has not been
cloned yet.
In addition to these ATP-dependent transport systems, the canalicular membrane also
contains several ATP-independent transport systems (Figure 1, right panel): Canalicular
excretion ofreduced glutathione (GSH) is driven by the membrane potential but the mole-
cular identity ofthis transport system remains currently unclear. Yi et al. [22] reported iso-
lation of a putative rat canalicular GSH transporter (RcGshT), but with the recent avail-
ability ofthe full E. coli genome it became apparent that the sequence ofRcGshT is an E.
coli gene and represents a cloning artifact [23, 24]. Canalicular bicarbonate secretion is
mediated via the Cl-/HCO3- exchanger belonging to a family of anion exchangers (AE)
which consists of several members, three of which (AEI, AE2, and AE3) are now well
characterized [25]. AE2 is encountered in various tissues, including the liver and secretory
epithelia, and plays a major role in mediating hepatic Cl-/HCO3- exchange. The AE2 pro-
tein is localized to both canaliculi (mainly in periportal hepatocytes) and the luminal side
of both terminal and interlobar bile ducts [26], consistent with a role for HCO3-excretion
Table 1. Canalicular transport systems in humans and rodents
Name Human Rat/Mouse Substrate(s)
I. ATP-dependent:
Canalicular bile salt export pump BSEP bsep Monovalent bile salts
(canalicular bile acid transporter) (cBAT) (cbat)
Canalicular conjugate export pump MRP2 mrp2 Divalent amphiphilic anionic
(cMOAT) (cmoat) conjugates with glutathione,
glucuronate, sulfate
Cation export pump MDR1 mdrla and b Bulky lipophilic cations
P-gp P-gp (typeII) (e.g., anthracyclines,
vinca alkaloids, and others)
Phospholipid export pump MDR3 mdr2 Phopholipids
P-gp P-gp
Sister ofP-glycoprotein SPGP spgp Unknown
(monovalent bile salts?)
II. ATP-independent:
Cl/HC03- anion exchanger AE2 ae2 HCO3-(in exchange for Cl-)
Canalicular GSH transporter RcGshT Reduced glutathione (GSH)
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and bile formation. In addition, a tertiary active HCOgJSO4- exchanger resides in the
canalicular membrane [27], although its function in bile formation remains to be estab-
lished. Table 1 summarizes the current nomenclature and functional features ofATP-depen-
dent and -independent transport systems at the canalicular membrane in humans and
rodents.
MODELS OF CHOLESTASIS AND CLINICAL CORRELATES
Cholestasis may result either from a functional defect in bile formation at the level of
the hepatocyte (hepatocellular cholestasis) or a mechanical impairment in bile secretion
and flow at the level ofbile ductules or ducts (ductular/ductal cholestasis). Several exper-
imental models ofcholestasis in rats have been developed that simulate human cholestat-
ic disease, such as sepsis-induced cholestasis (endotoxin [lipopolysaccharide, LPS]-treat-
ed rats), oral contraceptive-induced cholestasis/cholestasis of pregnancy (ethinylestradiol
[EE]-treated rats), and extrahepatic biliary obstruction (common bile duct ligation
[CBDL]) (Table 2). Despite their different etiology, each of these experimental models
result in marked impairment of canalicular excretion of bile acids and various (non-bile
acid) organic anions as demonstrated in isolated perfused rat livers, isolated rat hepato-
cytes, and isolated canalicular membrane vesicles. Interestingly, transport studies in
canalicular membrane vesicles from cholestatic animals have revealed changes in the
maximal transport velocity (Vm.) without significant changes in the relative affinity
(Michaelis constant, Km) [28-30]. These changes in Vmax would be consistent with a
decrease in the number of functional transport proteins as a consequence of either
decreased gene expression or targeting of the protein to the canalicular membrane as a
general mechanism ultimately leading to cholestasis in these different experimental mod-
els. Cloning of various transport systems has precipitated the availability of molecular
probes for several canalicular transport systems. Therefore, it has now become possible to
investigate potential changes in the expression of hepatocellular (canalicular) transport
systems in various experimental and clinical forms of cholestasis. In addition, knockout
animals and naturally occurring mutants deficient in specific canalicular transport func-
tions/systems have provided major insights in the physiological function of canalicular
transport systems and their role in the pathogenesis of cholestatic liver disease.
Table 2. Experimental rat models ofintrahepatic and obstructive cholestasis
Model Clinical correlate
Endotoxin, inflammatory cytokines Cholestasis of sepsis, total parenteral nutrition,
(e.g., TNF-ac, IL-l,B) cholestatic hepatitis (viral, alcoholic)
Hormones (ethinylestradiol, Oral contraceptive-induced cholestasis,
estradiol-17,B-glucuronide) cholestasis of pregnancy
Drugs (chlorpromazine, Drug-induced cholestasis
cyclosporin A,-diclofenac,
a-naphthylisothiocyanate)
Common bile duct ligation Extrahepatic biliary obstruction
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ALTERATIONS OF CANALICULAR TRANSPORT
SYSTEMS IN CHOLESTASIS
Since transport processes through the canalicular membrane generally represent the
rate-limiting step in bile formation, it may not be surprising that impairment of canalicu-
lar transport systems plays a major role in the pathogenesis of cholestasis. Impaired
canalicular excretory function will result in reduction of bile flow (pathophysiological
cholestasis) and in hepatocellular and systemic retention of potentially toxic endogenous
and exogenous biliary constituents (clinical cholestasis). Defects in transporter system
expression represent an important subset of mechanisms which can cause cholestasis.
While many ofthese changes may be regarded as secondary phenomenon to the retention
of biliary constituents within hepatic parenchyma, and thus a consequence rather than a
cause ofcholestasis, others, in particular genetic defects, may be considered to be the pri-
mary initiating cholestatic event. Nevertheless, reduced or even absent expression of a
gene or its product once cholestasis is established, may provide an explanation for the
ongoing functional impairment in bile formation. The following section attempts to cor-
relate functional and molecular alterations ofcanalicular transport systems in experimen-
tal models ofcholestasis (Table 3) and outlines potential implications ofthese changes for
the pathophysiology of cholestasis. Furthermore, molecular changes ofcanalicular trans-
porters in human cholestatic disorders are discussed whenever possible, although this
information is still very sparse.
Bile salts
The canalicular excretion of monovalent bile salts is mediated by a canalicular bile
acid transporter (cBAT/cbat) whereas the excretion of divalent sulfated and glucuronidat-
ed bile salt conjugates is mediated by the conjugate export pump (MRP2/mrp2) (see
below). Functional studies in isolated canalicular membrane vesicles have clearly demon-
strated inhibition ofATP-dependent transport of monovalent bile salts in various experi-
mental models ofcholestasis induced by LPS [29, 30], EE [28], cyclosporinA (CSA) [31].
Since theVmax ofATP-dependent canalicular bile acid transport is diminished in most of
these models of cholestasis [28-30], it could be expected that the expression of cbat is
down-regulated by these cholestatic agents/injuries. However, the information on the mol-
ecular expression of canalicular bile acid transporter(s) in these forms of cholestasis is
Table 3. Expression of canalicular transport systems in experimental models ofcholestasis.
Transporter Endotoxin Ethinylestradiol Biliary obstruction
Mrp2 mRNA fi mRNA *-> mRNA 4
protein 4I protein I protein >L
P-gp protein <-* protein <-* mRNA (mdrla,b)'t
protein I
Spgp protein 4 N. D. protein 4-
Ecto-ATPase mRNA <-> mRNA e-* mRNA <
protein <-> protein e-* protein <-+
4- decreased; <-+ unchanged; T increased; N.D. = not determined.
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limited since the "definitive" canalicular bile acid transporter (cBAT/cbat) has not been
cloned yet, although several candidate genes have been identified: In apreliminary report,
down-regulation of the sister of P-glycoprotein (spgp) [32] was demonstrated in LPS-
induced cholestasis and CBDL in rats [33]. This finding could be of interest, since spgp
is exclusively expressed in hepatocytes at the canalicular membrane to a similar extent as
the mdr2 isoform ofP-gp [32, 33] and some authors consider the spgp a candidate for the
canalicular bile acid transporter [34]. Alternative candidate genes include the (yet uniden-
tified) mammalian equivalent of a yeast gene (BATip) encoding an ATP-dependent trans-
porter for taurocholate in yeast vacuoles [35], and a group of 150 to 200-kDa plasma
membrane proteins overexpressed in a rat hepatoma-derived HTC cell lineresistant to gly-
cocholic acid [36, 37].
The expression of the canalicular enzyme and putative bile acid transporter Ca++-
Mg++-ecto-ATPase [38-40] was decreased after LPS and TNF-a administration in one
study [29], but not in two others [41, 42]. In addition, ecto-ATPase expression also did not
change during EE-induced cholestasis [43] and CBDL [44]. However, the true role of
ecto-ATPase in canalicular bile acid transport remains controversial, since the sequence of
this protein predicts a single membrane-spanning domain and the ATPase activity is ori-
ented toward the extracellular rather than the intracellular domain and can be uncoupled
from transport activity [39, 40], which does not conform to current expectations for an
ATP-dependent in-to-out transport protein [16, 45].
Amphiphilic anionic conjugates
The biliary excretion of various anionic conjugates (e.g., bilirubin diglucuronide,
GSH-conjugates, cysteinyl leukotrienes, oxidized glutathione (GSSG), dibromosufoph-
thalein (BSP), divalent bile acid glucuronides and sulfates) is also decreased in several
models of intrahepatic (LPS, EE) and extrahepatic cholestasis (CBDL) [28, 30, 46-50] .
Again, these functional studies have revealed decreasedVmax without changes in Km, con-
sistent with a change in the number offunctional transporters for these substrates. Recent
studies have demonstrated that the expression ofthe ratcanalicularconjugate exportpump
(mrp2) is profoundly decreased by LPS, EE, and CBDL at the protein level [51]. Mrp2
steady-state mRNA levels are also markedly decreased in LPS and CBDL animals, but
remain unchanged in EE-induced cholestasis. The findings in LPS-treated rats and CBDL
suggest that the reduction ofmrp2 protein levels may result at least in part from adecrease
in steady-state mRNA-levels, probably due to areduction in the rate ofgene transcription.
Although the half-life of the mrp2 protein is currently unknown, the rapid disappearance
ofthe protein within 16 hr after LPS suggests either that the half-life ofthis protein is nor-
mally short or that it is rapidly degraded during LPS-induced cholestasis. In contrast to
LPS and CBDL, mrp2 steady-state mRNA levels did not decline in EE-treated rats, sug-
gesting that the reduction ofmrp2 protein levels in this form of cholestasis occurs exclu-
sively by posttranslational mechanisms which remain to be determined.
Decreased mrp2 expression may provide amolecular mechanism explaining impaired
excretion ofa broad range ofendogenous and exogenous organic anions and thereby many
biochemical features of cholestasis, including conjugated hyperbilirubinemia and
impaired BSP and indocyanine green clearance. The effects on mrp2 expression are most
pronounced in LPS-induced cholestasis, consistent with elevations of(mostly conjugated)
serum bilirubin as the key-feature of sepsis-associated cholestasis ("jaundice of sepsis")
[52, 53]. Preliminary findings from our laboratory suggest, that inflammatory cytokines
such as tumor necrosis factor-a and interleukin-1 3 decrease mrp2 mRNA and protein lev-
els in primary rat hepatocytes in vitro, suggesting that the effects of LPS may be mediat-
ed through these proinflammatory cytokines. The clinical implications of these findings
may not only be restricted to the pathogenesis ofcholestasis of sepsis. Several other liver
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diseases such as total parenteral nutrition-induced cholestasis, alcoholic hepatitis and liver
cirrhosis are associated with significant portal vein and systemic endotoxemia and/or ele-
vated levels ofinflammatory cytokines [54-57]. In addition, down-regulation ofmrp2 may
have broader implications for the pathogenesis of intrahepatic cholestasis, since biliary
glutathione (GSH) excretion and thereby bile acid-independent bile flow is diminished in
mutant rats with congenitally absent mrp2 protein (see below). Thus, down-regulation of
mrp2 expression may represent a primary event in the pathogenesis of intrahepatic
cholestasis by reduction of bile acid-independent canalicular bile flow. Finally, decreased
mrp2 expression and function during cholestasis may also have important implications for
the metabolism and excretion of various potentially toxic endo- and xenobiotics [17, 58].
Drugs such as ampicillin and ceftriaxone are directly excreted into bile by mrp2 [14-16],
and their biliary excretion may be impaired during cholestasis [59, 60].
Mutant Groningen Yellow (GY)/transport deficient (TR-) and Eisai hyperbilirubine-
mic (EHBR) rats have a congenital defect in mrp2 function characterized by absent
canalicular transport for various endogenous and exogenous organic anions and are the rat
model for the Dubin-Johnson syndrome in humans [14]. Cross-breeding studies among
the individual mutant rat strains resulted in jaundiced offspring in either case, indicating
that GY/TR- and EHBR rats have an identical (autosomal recessive) defect. Recently, the
molecular basis for this hereditary defect in GY/TR- rats has been identified as a single-
nucleotide deletion in the mrp2 gene resulting in a frame shift which leads to the intro-
duction ofan early stop codon (at amino acid 401) [10]. In EHBR rats, a single nucleotide
substitution (but not deletion) also results in the introduction of a premature stop codon
(at amino acid 855) [61]. Both mutations lead to absence ofthe mrp2 protein from the liv-
ers of GY/TR- and EHBR rats, respectively [10, 11]. The untranslated mrp2 mRNA is
rapidly degraded explaining the very low to absent mRNA levels of mrp2 in these rats.
Recently, additional ATP-dependent canalicular conjugate export systems such as MRP-
like proteins (MLP 1 and 2) preserved in mutant EHBR rats have been identified [62] and
await furthermolecular characterization in models ofcholestatic liver disease. In addition,
ATP-independent, membrane potential-dependent transport routes for some mrp2/cmoat
substrates (e.g., bilirubin glucuronide) are preserved in the mutant rats [16]. Taken togeth-
er, these transport systems may explain residual canalicular conjugate transport undercon-
ditions with congenitally absent (mutant animals) or down-regulated mrp2 (cholestasis).
The human homologue of the canalicular conjugate export pump (MRP2) has also
recently been cloned [12, 13] and the MRP2 protein is absent in the Dubin-Johnson syn-
drome [63] as aresult ofamutation ofthe human MRP2 gene [64]. This syndrome is char-
acterized by conjugated hyperbilirubinemia and a selective abnormality in the biliary
excretion of a range of endogenous (bilirubin, coproporpyrin isomer series I) and exoge-
nous anionic conjugates (BSP, ICG conjugates, the oral cholecystographic agent iopanoic
acid), and is the human counterpart to the defect in GY/TR- and EHBR rats [14, 65].
However, patients with Dubin-Johnson syndrome are usually considered to be hyper-
bilirubinemic rather than cholestatic since there are no histological or biochemical signs
ofcholestasis. Whether bile flow is decreased in Dubin-Johnson syndrome patients, is not
known.
Organic cations
The expression of P-glycoproteins (P-gp) at the canalicular membrane is dramatical-
ly increased in CBDL and a-naphthylisothiocyanate-induced cholestasis [51, 66, 67] but
remains essentially unchanged in other forms ofcholestasis induced by LPS and EE [51],
although one group has described a slight decrease in canalicular P-gp content (by 15 per-
cent) in EE-induced cholestasis [67]. In rat liver, the increase in P-gp in CBDL and a-
naphthylisothiocyanate-induced cholestasis is mainly due to increased mdrla and lb gene
expression which is mainly accomplished through enhanced gene transcription [66]. In
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addition, the P-gp content of the canalicular membrane appears to be also regulated
through biliary excretion of P-gp. Interestingly, P-gp release into bile is markedly
impaired in CBDL, which could contribute to the increase in the hepatic P-gp content
[67]. The resulting higher level ofthe biliary cation efflux pump mdrl P-gp may facilitate
elimination ofpotentially toxic biliary constituents and thus prevent or limit hepatocellu-
lar damage in cholestasis. Indeed, the increased expression of mdrl P-gp results in
increased biliary excretion ofthe mdrl substrate vinblastine [67].
Knockout mice for the various mdrl isoforms have allowed an assessment of their
role in hepatobiliary transport physiology and the pathogenesis ofcholestasis. Mdrla(-/-)
knockout mice have normal bile flow and biliary organic cation excretion is only modest-
ly affected, since compensatory up-regulation of hepatic mdrlb expression occurs [68,
69]. Subsequently, mdrla/lb (-/-) double knockout mice have been developed to control
for compensatory (over-) expression of mdrlb Pgp in the liver [70]. These animals are
fully viable and, again, have normal bile flow, but biliary cation excretion is markedly
impaired. The consequences of a mdrl defect may not become evident, unless exogenous
toxins (that normally are eliminated via mdrl P-gp) are ingested with the food chain [69].
Mdrl substrates such as CSA inhibit ATP-dependent canalicular bile acid [31, 71] and
organic anion transport [71] in the rat, and accumulation of such substrates may indirect-
ly lead to cholestasis. Similarly, the phenotype of a human MDR1 defect would be expect-
ed to remain undetected unless challenged with a MDR1 substrate (e.g., under therapeu-
tic conditions). Therefore, it could be possible that some forms of drug-induced hepato-
cellular cholestasis should occur in patients with such a defect.
Phospholipids
Biliary excretion ofphospholipids is decreased in cholestasis induced by EE [66, 72]
and CSA [72], but is markedly increased in the first days following CBDL [66] and
decreases after prolonged CBDL [73]. Both the decrease in canalicular P-gp content
described in EE-induced cholestasis [67] and the marked increase in P-gp expression after
the first days of CBDL [51, 66, 67] would provide a potential molecular mechanism for
these functional alterations, although it was not demonstrated that these changes in P-gp
expression involve the mdr2 isoform (phospholipid export pump).
The results in mdr2 (-/-) knockout mice have shown that a defect in biliary phospho-
lipid secretion at the hepatocellular level can lead to cholangiopathy and severe liver dis-
ease [20, 75]. Therefore, the pathophysiology of a number of human neonatal and adult
choletastatic syndromes deserves re-evaluation in the light of a possible MDR3 (human
mdr2 homologue) defect. So far, MDR3 mRNA was found to be absent in one single
patient with a subtype of progressive familial intrahepatic cholestasis (type 3) character-
ized by elevated serum gamma-glutamyl transpeptidase activity, as well as bile duct pro-
liferation and inflammatory infiltrate in portal areas, thereby resembling the hepatic injury
observed in mdr2 (-/-) mice, and the biliary phospolipid levels were substantially
decreased in another patient with this disease [76]. However, no evidence for deficient or
reduced intrahepatic MDR3 mRNA levels in liver biopsy samples from patients with pri-
mary biliary cirrhosis was found by reverse transcription/competitive polymerase chain
reaction [77], suggesting that decreased MDR3 gene expression does notplay a role in the
pathogenesis ofprimary biliary cirrhosis.
Cholesterol
Biliary cholesterol excretion is impaired in various experimental models of cholesta-
sis such as EE-induced cholestasis [72], CSA-induced cholestasis [73] and CBDL [74].
The detailed molecular mechanism for these findings remains currently unclear although
impaired bile salt excretion observed in these models probably plays amajorrole [16, 78].
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Interestingly, a putative hepatic cholesterol carrier has been identified recently and awaits
further characterization in experimental models of cholestasis [79].
Glutathione
Biliary glutathione (GSH) excretion is markedly impaired in LPS-induced cholesta-
sis [50] and CBDL [46, 80] and results in increased hepatocelluar GSH levels in these
models ofcholestasis [48, 50, 80]. In contrast to the decrease ofbiliary GSH excretion in
livers from LPS-treated rats, GSH transport is normal in vitro in canalicular membrane
vesicles isolated from these animals [81]. This finding ofan apparentdiscrepancy between
the intact liver and vesicle transport of GSH is reminiscent of what has been described in
EHBR rats [82] with congenital absence ofmrp2 (see above) where defective biliary GSH
excretion is thought to be either a direct [24] or indirect effect [82, 83] ofthe mrp2 muta-
tion. Impaired biliary excretion of GSH in mutant rats and these models of cholestasis
could be best explained as a secondary defect due to cis-inhibition of canalicular GSH
transport from retained substrates for the defective mrp2 and/or loss of trans-stimulation
by these same substrates which are normally excreted into the bile canaliculus [82]. A
recent report raised the possibility that MRP may transport GSH in cell lines transfected
with MRP [84], and it was, therefore, suggested that its canalicular isoform MRP2/mrp2
might also directly participate in canalicular GSH transport [17, 24]. Although this would
provide a "unifying hypothesis" for both impaired biliary GSH excretion and impaired
excretion of amphiphilic anionic conjugates under conditions with a congenital (e.g.,
mutant rats) or acquired (e.g., LPS, CBDL) mrp2 defect, a major role for MRP2/mrp2 in
canalicular GSH transport appears unlikely, considering the fact that canalicular GSH
transport is electrogenic (but notATP-dependent) and bidirectional (but not unidirection-
al) as opposed to transport mediated by MRP2/mrp2 [83].
Bicarbonate
Biliary HC03- excretion is markedly impaired in EE-induced cholestasis [85] and to
a lesser degree in LPS-induced cholestasis [50]. However, in EE-treated animals, canalic-
ular Cl7HC03- anion exchanger activity and its hormonal regulation are normal, and
impaired biliary HCO3- excretion is apparently caused by regurgitation ofbiliary HC03-
via leaky tightjunctions from the bile canaliculus into the liver sinusoids [85]. In contrast,
CBDL leads to increased biliary HCO3- excretion from proliferating bile ductules, par-
ticularly when stimulated with secretin [74]. Nomoleculardata are so far available regard-
ing the expression of Cl-/HCO3- anion exchanger (AE2) genes in these experimental
models ofcholestasis in rodents. However, recent studies in humans have revealed abnor-
mal expression ofAE2 in liver from patients with primary biliary cirrhosis [86-88]. AE2
immunoreactivity at canaliculi and bile ducts was decreased in such livers, and AE2
mRNA levels in liver tissue from these patients were also reduced. Since Cl-/HCO3--
exchange activity is believed to be essential to secretion of both canalicular and ductular
bile, decreased expression of AE2 in the liver may lead to impaired bile secretion.
Diminished AE2 expression has also been reported in salivary glands from patients with
primary biliary cirrhosis and Sicca syndrome [87], which may indicate a more generalized
epithelial "HC03- secretory failure" in PBC.
SUMMARY AND CONCLUSIONS
The canalicular excretion of bile acids and various non-bile acid organic anions is
impaired in several experimental models ofcholestasis, such as endotoxin (LPS)-induced
cholestasis, estrogen (EE)-induced cholestasis and bile duct ligation (CBDL). Recent
advances in molecular biology have permitted studies on the expression of canalicular
373374 Trauner: Canalicular transporters in cholestasis
transport proteins in these models of cholestasis, and have provided new insights in the
molecular pathogenesis ofcholestasis. LPS, EE, and CBDL all down-regulate the expres-
sion ofthe canalicular conjugate export pump (mrp2) which may explain impaired excre-
tion of amphiphilic anionic conjugates (e.g., conjugated bilirubin) in these forms of
cholestasis. Down-regulation of transporter genes such as mrp2 may represent an impor-
tant general mechanism ofcholestasis in these experimental models. The expression ofP-
glycoproteins remains essentially unchanged in LPS- and EE-induced cholestasis, but
increases dramatically following CBDL due to the mdrl isoform, which may reflect an
attempt of the hepatocyte to facilitate the biliary excretion of lipophilic cholephiles
retained in the liver in cholestasis. Although canalicular bile salt transport is also impaired
in cholestasis, conclusive molecular studies have to await the cloning of the "definitive"
canalicular bile acid transporter (cBAT/cbat). With the increasing availability of molecu-
lar probes for these transport systems in humans, new information on the molecular regu-
lation of canalicular transport proteins in human cholestatic liver diseases should bring
new insights into their pathophysiology and treatment.
Added in proof: Since submission of this manuscript the sister of P-glycoprotein
(spgp) has been identified as the canalicular bile acid transporter (cBAT/cbat) of mam-
malian liver (Gerloffet al., Hepatology 26:358A, 1997 and J. Biol. Chem. in press, 1998).
Mutations of the human SPGP gene could be responsible for progressive familial intra-
hepatic cholestasis type 2 (Byler's Syndrome) (Strautnieks et al., Am. J. Hum. Genet.
61:630-633, 1997). Another subtype, progressive familial intrahepatic cholestasis type 3
is caused by a mutation of the human MDR3 gene resulting in the absence of MDR3 P-
glycoprotein in the liver and reduced/absent biliary phospholipid excretion in these
patients (deVree et al., Proc. Natl. Acad. Sci. U.S.A. 95:282-287, 1998). Progressive
familial intrahepatic cholestasis type I (Byler's Disease) and benign recurrent intrahepat-
ic cholestasis appear to be due to a mutation of the same gene, despite their entirely dif-
ferent phenotypes and prognosis. This gene (called FIC1) normally encodes a P-type
ATPase which is expressed more in the small intestine than in liver and likely plays a role
in the enterohepatic circulation of bile acids (Bull et al., Nature Genetics 18:219-224,
1998).
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